The National Law Journal spoke with Arent Fox Complex Litigation Practice Leader Jacques Smith last week about key trends in FCA enforcement for the Health Care industry.
Several recent surveys and reports by governance and trade associations provide a useful overview of the duties, roles, challenges, and internal relationships of the corporate general counsel, as well as governing board needs and priorities.
Join us for a virtual discussion of telehealth’s current state of play from a boots-on-the-ground provider perspective, as well as views from Capitol Hill and CMS.
On Thursday, the Senate Finance Committee held a confirmation hearing for two of the most important health policy officials nominated by President Biden, Chiquita Brooks-LaSure (Administrator, Centers for Medicare and Medicaid Services) and Andrea Palm (Deputy Secretary).
Congress recently passed two bills that are designed to educate patients and prescribers about biosimilars and thereby encourage their use and to close a loophole in existing law that allows certain branded drugs to retain longer market exclusivity.
Health Care Practice Leader Douglas Grimm will present at the Virginia-DCHFMA Spring Education Virtual Conference on April 15, 2021, regarding the current state of CARES Act’s Provider Relief Fund.
Health Care Partner Stephanie Trunk is teaching a Lawline course titled “What the Biden Administration Means for Drug Pricing, Coverage and Reimbursement” on April 12, 2021, at 3:30pm ET.
Hospitals everywhere in the United States should take note: CMS announced on March 26, 2020, that it is lifting its extended 30-day survey suspension for hospitals. Survey activity will now resume.
Applicable drug manufacturers and group purchasing organizations that are subject to the reporting rules under the Open Payments System are reminded that March 31, 2021, is the final day to submit and attest to data for the June 2021 publication of Program Year 2020 data.
Texas Health and Human Services announced that beginning April 1, 2021, drug manufacturers who wish for their products to be added to the Texas Drug Code Index (the Texas Medicaid formulary) must create an electronic account.
Immediately at issue was Lilly and Company and Lilly USA’ refusal to sell covered outpatient drugs at the 340B Ceiling Price to contract pharmacies acting as agents for 340B Covered Entities. Several 340B Covered Entities had petition for a hearing by the ADR panel.
The Governance Institue published an article explaining why governing boards may want to engage with legal counsel and others on the executive team to understand how the Final Rule would impact their organization’s operations.
The American Rescue Plan Act of 2021, signed into law by President Biden on March 11, 2021, is a $1.9 trillion aid package that provides assistance to businesses and individuals experiencing financial hardship due to COVID-19.
Schiff Hardin advised CNS Pharmaceuticals, Inc. in connection with its public offering of 5,750,000 shares of common stock and 2,875,000 warrants to purchase common stock for gross proceeds of $11.5 million.
